Redsense Medical received more than MSEK 4 worth of orders from the US in July and August 2019
Following a Q2 which marked a new record level for the company, Redsense has during the months of July and August 2019 already received orders from the US with a total value surpassing MSEK 4. Larger US providers have publically communicated their intention to continue to improve and increase their operations in home hemodialysis. This is also in line with the US Government’s new initiative to promote home hemodialysis.
“We are happy to see a continued increase in the use of Redsense in the US, and we are expecting more orders during the fall. There is a trend among dialysis providers to move more towards home hemodialysis, which opens interesting opportunities for Redsense Medical”, says Patrik Byhmer, CEO, Redsense Medical AB.
For more information, please contact:
Patrik Byhmer, CEO Redsense Medical AB (publ)
Phone: +46 35 10 60 30
info@redsensemedical.com
ABOUT REDSENSE MEDICAL
Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.